GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (XCNQ:AION) » Definitions » Debt-to-EBITDA

Aion Therapeutic (XCNQ:AION) Debt-to-EBITDA : -2.17 (As of Jul. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aion Therapeutic Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aion Therapeutic's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$2.50 Mil. Aion Therapeutic's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$0.00 Mil. Aion Therapeutic's annualized EBITDA for the quarter that ended in Jul. 2024 was C$-1.16 Mil. Aion Therapeutic's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2024 was -2.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aion Therapeutic's Debt-to-EBITDA or its related term are showing as below:

XCNQ:AION' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.78   Med: -0.31   Max: -0.07
Current: -0.41

During the past 8 years, the highest Debt-to-EBITDA Ratio of Aion Therapeutic was -0.07. The lowest was -10.78. And the median was -0.31.

XCNQ:AION's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs XCNQ:AION: -0.41

Aion Therapeutic Debt-to-EBITDA Historical Data

The historical data trend for Aion Therapeutic's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aion Therapeutic Debt-to-EBITDA Chart

Aion Therapeutic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Debt-to-EBITDA
Get a 7-Day Free Trial -3.98 -0.07 -0.18 -10.78 -0.34

Aion Therapeutic Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.85 -1.83 -1.62 -0.10 -2.17

Competitive Comparison of Aion Therapeutic's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aion Therapeutic's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Debt-to-EBITDA falls into.



Aion Therapeutic Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aion Therapeutic's Debt-to-EBITDA for the fiscal year that ended in Apr. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.082 + 0) / -6.074
=-0.34

Aion Therapeutic's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.503 + 0) / -1.156
=-2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jul. 2024) EBITDA data.


Aion Therapeutic  (XCNQ:AION) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Aion Therapeutic Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aion Therapeutic Business Description

Traded in Other Exchanges
Address
700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.
Executives
Ismail Abdul Fattah Director or Senior Officer of 10% Security Holder
Douglas Craig Wilson Director or Senior Officer of 10% Security Holder
John Graham Simmonds Director, Senior Officer

Aion Therapeutic Headlines

No Headlines